CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

About CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CBAY
  • CUSIP: N/A
  • Web: www.cymabay.com
Capitalization:
  • Market Cap: $344.8 million
  • Outstanding Shares: 43,756,000
Average Prices:
  • 50 Day Moving Avg: $7.59
  • 200 Day Moving Avg: $5.82
  • 52 Week Range: $1.15 - $9.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.65
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.79 million
  • Price / Sales: 71.98
  • Book Value: $0.07 per share
  • Price / Book: 112.57
Profitability:
  • EBITDA: ($20,290,000.00)
  • Return on Equity: -425.44%
  • Return on Assets: -122.91%
Debt:
  • Debt-to-Equity Ratio: 2.15%
  • Current Ratio: 1.49%
  • Quick Ratio: 1.49%
Misc:
  • Average Volume: 855,312 shs.
  • Beta: 2.22
  • Short Ratio: 0.5
 

Frequently Asked Questions for CymaBay Therapeutics (NASDAQ:CBAY)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc. (NASDAQ:CBAY) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.06. View CymaBay Therapeutics' Earnings History.

When will CymaBay Therapeutics make its next earnings announcement?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for CymaBay Therapeutics.

Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?

9 analysts have issued 12-month price objectives for CymaBay Therapeutics' stock. Their predictions range from $12.00 to $16.00. On average, they expect CymaBay Therapeutics' stock price to reach $14.00 in the next year. View Analyst Ratings for CymaBay Therapeutics.

What are analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Interim Phase 2 data as good as it gets. Seladelpar’s efficacy in PBC was established in a Phase 2 trial that tested 50mg or 200mg daily doses. Problematic were safety signals that led to termination of the study." (9/19/2017)
  • 2. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (9/18/2017)
  • 3. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
  • 4. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest during the month of September. As of September 29th, there was short interest totalling 1,489,737 shares, an increase of 35.1% from the September 15th total of 1,102,943 shares. Based on an average daily trading volume, of 838,810 shares, the days-to-cover ratio is currently 1.8 days. Currently, 3.7% of the shares of the company are sold short.

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:

  • Robert James Wills Ph.D., Chairman of the Board
  • Sujal Shah, Interim President, Interim Chief Executive Officer, Chief Financial Officer
  • Charles A. McWherter Ph.D, Senior Vice President, Chief Scientific Officer
  • Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
  • Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance
  • Pol F. Boudes M.D., Chief Medical Officer
  • Robert Booth Ph.D., Director
  • Caroline Loewy, Director
  • Evan A. Stein M.D. Ph.D., Director
  • Paul F. Truex, Director

How do I buy CymaBay Therapeutics stock?

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CymaBay Therapeutics stock can currently be purchased for approximately $7.88.


MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (77.66% upside)
Consensus Price Target History for CymaBay Therapeutics (NASDAQ:CBAY)
Price Target History for CymaBay Therapeutics (NASDAQ:CBAY)
Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Cantor FitzgeraldReiterated RatingBuy$16.00HighView Rating Details
8/23/2017Leerink SwannInitiated CoverageOutperform -> Outperform$12.00LowView Rating Details
8/18/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$15.00HighView Rating Details
8/11/2017Ifs SecuritiesDowngradeStrong-Buy -> OutperformHighView Rating Details
7/25/2017Piper Jaffray CompaniesReiterated RatingPositive -> Overweight$12.00LowView Rating Details
7/20/2017CIBCReiterated RatingOutperform -> Outperform$8.00 -> $15.00MediumView Rating Details
7/20/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$8.00 -> $15.00MediumView Rating Details
7/20/2017Citigroup Inc.Reiterated RatingOutperform$8.00 -> $15.00MediumView Rating Details
7/17/2017HC WainwrightBoost Price TargetBuy$7.00 -> $12.00HighView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings History by Quarter for CymaBay Therapeutics (NASDAQ CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.19)N/AView Earnings Details
8/10/2017Q2 2017($0.25)($0.31)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.27)($0.20)$4.79 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.28)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.31)($0.25)ViewListenView Earnings Details
8/9/2016Q2($0.32)($0.30)ViewN/AView Earnings Details
5/11/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015Q1 2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.46)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.48)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
2017 EPS Consensus Estimate: ($0.85)
2018 EPS Consensus Estimate: $0.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.28)($0.28)($0.28)
Q2 20172($0.29)($0.25)($0.27)
Q3 20173($0.20)($0.14)($0.17)
Q4 20173($0.21)$0.03($0.12)
Q1 20181($0.28)($0.28)($0.28)
Q2 20181$0.48$0.48$0.48
Q3 20181$0.35$0.35$0.35
Q4 20181($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 25.91%
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Kurt Von EmsterDirectorSell108,876$7.85$854,676.60View SEC Filing  
9/29/2017Kurt Von EmsterDirectorSell211,124$8.09$1,707,993.16View SEC Filing  
8/1/2017Robert James WillsDirectorBuy5,000$6.84$34,200.00View SEC Filing  
7/20/2017Charles McwherterSVPBuy5,000$7.43$37,150.00View SEC Filing  
7/20/2017Sujal ShahInsiderBuy10,000$7.34$73,400.00View SEC Filing  
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.00View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CymaBay Therapeutics (NASDAQ:CBAY)
Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
Source:
Loading headlines, please wait.

Social

Chart

CymaBay Therapeutics (CBAY) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.